![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/28/2888855/0/en/AC-Immune-to-Present-at-the-Jefferies-Global-Healthcare-Conference-in-June-2024.html
https://www.biopharmadive.com/news/takeda-alzheimers-ac-immune-immunotherapies/715913/
https://www.globenewswire.com/news-release/2024/05/13/2880203/0/en/AC-Immune-Reports-First-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/13/2880195/0/en/AC-Immune-and-Takeda-Sign-Exclusive-Option-and-License-Agreement-for-Active-Immunotherapy-Targeting-Amyloid-Beta-for-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2024/03/14/2846139/0/en/AC-Immune-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/02/22/2833535/0/en/AC-Immune-Announces-Upcoming-Presentations-at-AD-PD-2024.html
https://www.fiercebiotech.com/biotech/roches-genentech-returns-alzheimers-assets-ac-immune-cutting-18-year-tie-biotech
https://www.globenewswire.com//news-release/2024/01/22/2812913/0/en/AC-Immune-to-Regain-Global-Rights-to-Crenezumab-and-Semorinemab.html
https://www.globenewswire.com//news-release/2024/01/03/2803284/0/en/AC-Immune-Progress-Update-on-Phase-2-Active-Immunotherapy-Clinical-Pipeline-for-Alzheimer-s-and-Parkinson-diseases.html